ERBB2 and breast carcinoma: This is the first study to the authors’ knowledge to analyze the HER2/CEP17 FISH ratio as a potential biomarker to predict pCR in HER2+ breast cancer patients who received neoadjuvant dual HER2-targeted therapies without cytotoxic chemotherapy.